Drugs / MVA RH5
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03435874 | Apr 2018 → Jul 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02181088 | Aug 2014 → Oct 2015 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA RH5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03435874 ↗ |
| Modality | Vaccine | “two new malaria vaccines, ChAd63 RH5 and MVA RH5” NCT02181088 ↗ |
| Route | Intramuscular | “both vaccines will be administered by the intramuscular route” NCT03435874 ↗ |